Biomarkers for ovarian cancer
The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.
1. A method of qualifying ovarian cancer status in a subject comprising:
(a) measuring using mass spectrometry or an immunoassay, biomarkers comprising modified ApoA1, and one or more modified transthyretin selected from the group consisting of cysteinylated transthyretin, sulfonated transthyretin, CysGly modified transthyretin, glutathionylated transthyretin, and combinations thereof, and
(b) comparing the level of one or more of modified ApoA1 and modified transthyretin in said sample to a control level, wherein a decrease in said level of modified ApoA1 and modified transthyretin is indicative of ovarian cancer.
2. The method of claim 1 further comprising:
(c) managing subject treatment based on the status.
3. The method of claim 2 , wherein managing subject treatment is selected from ordering more tests, performing surgery, and taking no further action.
4. The method of claim 2 further comprising:
(d) measuring the at least one biomarker after subject management.
5. The method of claim 1 wherein the ovarian cancer status is selected from the group consisting of the subject's risk of cancer, the presence or absence of disease, the stage of disease and the effectiveness of treatment of disease.
6. The method of claim 5 further comprising measuring at least one known biomarker in a sample from the subject and correlating measurement of the known biomarker with ovarian cancer status.
7. The method of claim 6 , wherein the known biomarker is selected from CA125, CAI25 II, CA15-3, CA19-9, CA72-4, CA 195, tumor associated trypsin inhibitor (TATI), CEA, placental alkaline phosphatase (PLAP), Sialyl TN, galactosyltransferase, macrophage colony stimulating factor (M-CSF, CSF-1), lysophosphatidic acid (LPA), 110 kD component of the extracellular domain of the epidermal growth factor receptor (p110EGFR), tissue kallikreins, e.g., kallikrein 6 and kallikrein 10 (IMES-1), prostasin, HE4, creatine kinase B (CKB), LASA, HER-2/neu, urinary gonadotropin peptide, Dianon NB 70/K, Tissue peptide antigen (TPA), osteopontin and haptoglobin, and protein variants, cleavage forms, and isoforms of the markers.
8. The method of claim 1 , wherein the modified transthyretin is cysteinylated transthyretin.
9. The method of claim 1 comprising measuring modified ApoA1, cysteinylated transthyretin, sulfonated transthyretin, CysGly modified transthyretin, and glutathionylated transthyretin.
10. The method of claim 1 wherein the correlating is performed by a software classification algorithm.
11. The method of claim 1 wherein the sample is selected from blood, serum and plasma.